BE665076A - - Google Patents
Info
- Publication number
- BE665076A BE665076A BE665076A BE665076A BE665076A BE 665076 A BE665076 A BE 665076A BE 665076 A BE665076 A BE 665076A BE 665076 A BE665076 A BE 665076A BE 665076 A BE665076 A BE 665076A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- gelatin
- degraded
- oxypolygelatin
- crosslinked
- Prior art date
Links
- 108010010803 Gelatin Proteins 0.000 claims description 24
- 229920000159 gelatin Polymers 0.000 claims description 24
- 239000008273 gelatin Substances 0.000 claims description 24
- 235000019322 gelatine Nutrition 0.000 claims description 24
- 235000011852 gelatine desserts Nutrition 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 16
- 108010014241 oxypolygelatine Proteins 0.000 claims description 15
- 239000003381 stabilizer Substances 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000011149 active material Substances 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229940015043 glyoxal Drugs 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical group O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000037358 bacterial metabolism Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 9
- 208000000474 Poliomyelitis Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 206010043376 Tetanus Diseases 0.000 description 6
- 206010013023 diphtheria Diseases 0.000 description 6
- 108010023197 Streptokinase Proteins 0.000 description 5
- 229960005202 streptokinase Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 201000005702 Pertussis Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940088623 biologically active substance Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940068004 oxypolygelatine Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- -1 oxy- Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE665076A BE665076A (en:Method) | 1963-12-23 | 1965-06-08 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE641705A BE641705A (en:Method) | 1963-12-23 | 1963-12-23 | |
| BE665076A BE665076A (en:Method) | 1963-12-23 | 1965-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE665076A true BE665076A (en:Method) | 1965-12-08 |
Family
ID=25655617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE665076A BE665076A (en:Method) | 1963-12-23 | 1965-06-08 |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE665076A (en:Method) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2371927A1 (en) * | 1976-11-29 | 1978-06-23 | Connaught Lab | Anti:poliomyelitis vaccine contg. attenuated viruses - is stabilised by suspending in tris-hydroxy-methyl-amino-methane and L-cystine opt. with acid hydrolysed gelatin |
| FR2425245A1 (fr) * | 1978-05-12 | 1979-12-07 | Sumitomo Chemical Co | Procede pour la preparation d'une composition injectable d'urokinase |
| EP0006671A3 (en) * | 1978-07-03 | 1980-02-06 | Hans Dr. Ing. Muller | Process for the conservation of living microorganisms |
| EP0028563A1 (en) * | 1979-10-29 | 1981-05-13 | Merck & Co. Inc. | Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer |
-
1965
- 1965-06-08 BE BE665076A patent/BE665076A/fr unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2371927A1 (en) * | 1976-11-29 | 1978-06-23 | Connaught Lab | Anti:poliomyelitis vaccine contg. attenuated viruses - is stabilised by suspending in tris-hydroxy-methyl-amino-methane and L-cystine opt. with acid hydrolysed gelatin |
| FR2425245A1 (fr) * | 1978-05-12 | 1979-12-07 | Sumitomo Chemical Co | Procede pour la preparation d'une composition injectable d'urokinase |
| EP0006671A3 (en) * | 1978-07-03 | 1980-02-06 | Hans Dr. Ing. Muller | Process for the conservation of living microorganisms |
| EP0028563A1 (en) * | 1979-10-29 | 1981-05-13 | Merck & Co. Inc. | Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE897276A (fr) | Compositions d'interferon b stales et procede de stabilisation l'interferon b | |
| US4206200A (en) | Stabilizer for polysaccharides | |
| EP0841942B1 (fr) | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu | |
| CN1149283C (zh) | 稳定谷氨酰胺转移酶制剂及其生产方法 | |
| FR2475900A1 (fr) | Complexe vaccinal contenant un antigene specifique et vaccin le contenant | |
| FR2530472A1 (fr) | Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur | |
| EP0353108B1 (fr) | Procédé de stabilisation des vaccins et associations de vaccins à virus atténués conservés sous forme lyophilisée, et compositions obtenues | |
| BE1008163A5 (fr) | Nouveaux oligodesoxyribonucleotides a activite anti-ischemique et leur preparation. | |
| EP0013851A1 (fr) | Protéoglycanes bactériens purifiés, procédé pour leur préparation et vaccin les contenant | |
| WO1995003826A1 (fr) | Preparations d'immunoglobulines stabilisees et procede pour leur preparation | |
| BE665076A (en:Method) | ||
| EP0071515B1 (fr) | Procédé d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application à la préparation de vaccins | |
| FR2634125A1 (fr) | Composition pharmaceutique a base de superoxyde dismutase | |
| EP1357895A2 (fr) | Composition vaccinale et procede de stabilisation | |
| EP1981549B1 (fr) | Procede d'inactivation virale par chauffage a sec | |
| JPH0228319B2 (en:Method) | ||
| Gardner et al. | Relative stability of pertussis vaccine preserved with merthiolate, benzethonium chloride, or the parabens | |
| CH412201A (fr) | Procédé de stabilisation d'un produit à base de virus antigène labile | |
| FR2471189A1 (fr) | Procede de preparation d'un agent anti-tumoral comprenant un composant cellulaire de streptococcus pyogenes | |
| EP0383645A1 (fr) | Procédé de fabrication du facteur antihémophilique (FVIIIc) ayant une très haute pureté. | |
| BE641705A (en:Method) | ||
| CH423098A (fr) | Procédé de préparation d'un vaccin staphylococcique | |
| AU2005203171B2 (en) | Botulinum toxin pharmaceutical compositions | |
| BE622212A (en:Method) | ||
| EP0106831A2 (fr) | Souches modifiées du virus de la diarrhée virale bovine, leur préparation et vaccins les contenant |